Treating Prostate Cancer
- Duran Duran guitarist Andy Taylor shared that he’s battling stage four prostate cancer via a letter read at the band’s recent Rock and Roll Hall of Fame induction ceremony.
- Symptoms of prostate cancer are inconsistent and hard to pinpoint but may include changes in urinary function like urinating more or less often or waking up at night to go more than usual.
- There are treatment options available for people facing late-stage prostate cancer. In fact, an oral medication called Nubeqa (darolutamide) was just approved by the Food and Drug Administration (FDA) in August 2022 for use in combination with Taxotere (docetaxel) for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).
- Nubueqa is in a category of anti-androgens or anti-testosterone drugs, and it works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.
The English new wave band’s original guitarist was notably absent from his band’s Rock and Roll Hall of Fame induction ceremony at Microsoft Theater in Los Angeles, California, on November 5, 2022. But after his bandmates read a letter written by Taylor himself, the audience understood why.
Read More“Although my current condition is not immediately life-threatening, there is no cure,” he wrote. “Recently, I was doing OK after some very sophisticated life-extending treatment, that was until a week or so ago when I suffered a setback, and despite the exceptional efforts of my team, I had to be honest in that both physically and mentally, I would be pushing my boundaries.
“However, none of this needs to or should detract from what this band (with or without me) has achieved and sustained for 44 years.”
"Truly sorry and massively disappointed" he couldn’t be in attendance at the ceremony, Taylor said he was “overjoyed” by the band’s award and massively proud of his “four brothers” singer Simon Le Bon, keyboardist Nick Rhodes, bassist John Taylor and drummer Roger Taylor.
"I often doubted the day would come,” he wrote. “I'm sure as hell glad I'm around to see the day.”
Understanding Prostate Cancer
Prostate cancer is the most common cancer in American men except for skin cancers. About one in eight men will be diagnosed with prostate cancer during his lifetime. The disease begins in the walnut-shaped prostate gland located between the rectum and bladder. This gland produces the fluid that nourishes sperm.
When Should I Get Tested for Prostate Cancer?
Symptoms of the disease are inconsistent and hard to pinpoint.
"Prostate cancer is a very odd disease in that it doesn't have a particular symptom," Dr. Edwin Posadas, director of translational oncology and the medical director of the Urologic Oncology Program at Cedars-Sinai, explained.
But changes in urinary function like urinating more or less often or waking up at night to go more than usual could be a sign of the disease. However, it's important to note that these potential symptoms could also could be caused by a urinary tract infection or even an enlargement of the prostate gland (which is not cancer).
There's No One Definitive Symptom for Prostate Cancer, But There Are Clues
Doctors that have spoken with SurvivorNet shared a hopeful outlook when considering a prostate cancer diagnosis because there are many treatment options, and there's been significant treatment progress over the past decade.
Surgical and radiation options, for example, have made improvements in reducing side effects of treatment while still providing excellent cure rates. Even for men with an advanced-stage diagnosis, many new options exist to treat prostate cancer and help them maintain an excellent quality of life.
Treating Late-Stage Prostate Cancer Like Andy Taylor’s
We don’t know too many details about Andy Taylor’s prostate cancer battle, but we do know people with late-stage prostate cancer usually undergo some combination of treatments. And new approvals are being made all the time to give people more options to treat thus advanced disease.
The drug nubeqa (also known as darolutamide), for instance, was just approved by the Food and Drug Administration (FDA) in August 2022 for use in combination with taxotere (docetaxel) for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).
RELATED: How Is Nubeqa Used to Treat Advanced Prostate Cancer?
This oral medication is in a category of anti-androgens or anti-testosterone drugs, and it works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.
How Does Androgen Deprivation Therapy Help Shrink Prostate Cancer Tumors?
“If we take away testosterone, we can shrink down the tumor and hold it in check for often years and years and years,” Dr. Stephen Freedland, a urologist at Cedars-Sinai Medical Center, previously told SurvivorNet of androgen deprivation therapy in prostate cancer.
RELATED: How to Treat Late-Stage Prostate Cancer: Treatment Developments
Xtandi (enzalutamide) is another androgen deprivation therapy. This oral medication is FDA-approved to treat non-metastatic (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).
Erleada (apalutamide) is another FDA-approved oral medication for advanced prostate cancer. It can be used for people with metastatic castrate-sensitive prostate cancer (mCRPC).
In addition to androgen depravation drugs, PARP inhibitors can also be a good option for some people with advanced prostate cancer. These drugs work by stopping the activity of poly (ADP-ribose) polymerase, a protein involved in DNA repair. This, in turn, causes DNA to be unable to repair itself in cancer cells and therefore leads to the death of these cancer cells. The two PARP inhibitors currently approved by the FDA are lynparza (olaparib) and rubraca (rucaparib). They are specifically approved for use in people with metastatic castration-resistant prostate cancer (mCRPC) this distinction means the prostate cancer has spread beyond the prostate and does not respond to hormone therapy.
In March 2022, another FDA approval paved the way for the drug pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Some prostate cancers the express the protein PSMA which can be targeted with medication.
"The approval of lutetium is a major step in the development of personalized treatment for advanced prostate cancer," Dr. David Penson, of Vanderbilt University Medical Center, told SurvivorNet in a previous interview. "This agent specifically targets PSMA-positive metastasis and represents the first theranostic agent for use in castration-resistant metastatic prostate cancer."
This medication is considered “theranostic” because it combines diagnostic and therapeutic capabilities by identifying the presence of PSMA on a patient's cancer cells and then treating it directly with minimal exposure to normal tissues.
In addition to the above treatments, there are plenty of other options for advanced prostate cancer patients to turn to when dealing with their disease. Talk with your doctor about your options and even ask if a clinical trial might be right for you.
Learn more about SurvivorNet's rigorous medical review process.